A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
Stocktwits on MSN
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction
Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA ...
An AAV vector genome integration event associated with PLAG1 overexpression was identified in a preliminary analysis of the resected tumor.
The US Food and Drug Administration (FDA) has placed a clinical hold on Regenxbio’s investigational gene therapy, RGX-111, ...
As of Wednesday, January 28, REGENXBIO Inc.’s RGNX share price has dipped by 18.49%, which has investors questioning if this is right time to buy.
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...
The FDA halted clinical trials of two gene therapies on account of a tumor found in a Hurler syndrome patient who had received RGX-111.
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...
The company said that the FDA hold has impacted two experimental gene therapies, RGX-111 and RGX-121. ・REGENXBIO added that ...
Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs ...
Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results